{
  "schema_version": "1.1",
  "scope": "US; bounded product facts, not prescribing guidance",
  "checked": "2026-09-15",
  "drugs": [
    {
      "id": "veozah",
      "name": "Veozah",
      "ingredient": "fezolinetant",
      "form": "Oral tablet",
      "routine": "45 mg once daily",
      "indication": "Menopausal moderate-to-severe hot flashes",
      "safety": "Liver injury boxed warning; baseline tests, monthly for 3 months, then months 6 and 9.",
      "source": "https://www.astellas.com/us/system/files/veozah_uspi.pdf",
      "source_locator": "Highlights; sections 1, 2 and 5",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "lynkuet",
      "name": "Lynkuet",
      "ingredient": "elinzanetant",
      "form": "Oral capsule",
      "routine": "Two 60 mg capsules once daily at bedtime; interaction adjustments may apply",
      "indication": "Menopausal moderate-to-severe hot flashes",
      "safety": "Liver tests before treatment and at 3 months; daytime impairment, pregnancy and seizure warnings.",
      "source": "https://labeling.bayerhealthcare.com/html/products/pi/Lynkuet_PI.pdf",
      "source_locator": "August 2026 label; sections 1, 2 and 5",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "brisdelle",
      "name": "Brisdelle",
      "ingredient": "paroxetine mesylate, 7.5 mg formulation",
      "form": "Oral capsule",
      "routine": "7.5 mg once daily at bedtime",
      "indication": "Menopausal moderate-to-severe vasomotor symptoms",
      "safety": "SSRI boxed warning; tamoxifen and serotonergic interactions need review.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=502311b3-b617-4cbd-a3ab-a60f2c62880a",
      "source_locator": "Sections 1, 2, 5 and 7",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "paroxetine-7-5",
      "name": "Paroxetine 7.5 mg",
      "ingredient": "paroxetine mesylate",
      "form": "Oral capsule",
      "routine": "7.5 mg once daily at bedtime",
      "indication": "Menopausal moderate-to-severe vasomotor symptoms",
      "safety": "Not a psychiatric-treatment formulation; exact generic substitution requires pharmacy verification.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1383d713-79b9-45bd-bd06-65707f28bc99",
      "source_locator": "Sections 1, 2 and 7",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "oral-estradiol",
      "name": "Oral estradiol",
      "ingredient": "estradiol",
      "form": "Oral tablet",
      "routine": "Strength and schedule depend on the prescription",
      "indication": "Includes menopausal vasomotor symptoms",
      "safety": "Systemic estrogen precautions apply; discuss the complete prescribed regimen.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4936878-1643-4e7f-9b0d-e4957935aef2",
      "source_locator": "Indications; dosage; warnings",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "divigel",
      "name": "Divigel",
      "ingredient": "estradiol",
      "form": "Skin gel",
      "routine": "Daily application; prescribed packet strength matters",
      "indication": "Menopausal moderate-to-severe vasomotor symptoms",
      "safety": "Systemically absorbed estrogen; follow application and contact precautions.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59e610dc-883e-4f07-9ec6-a5841b0bf9fb",
      "source_locator": "Sections 1, 2 and 5",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "minivelle",
      "name": "Minivelle",
      "ingredient": "estradiol",
      "form": "Skin patch",
      "routine": "Twice-weekly replacement (every 3–4 days), under the prescription",
      "indication": "Hot flashes and osteoporosis prevention; indication varies by strength",
      "safety": "The manufacturer limits the 0.025 mg/day strength to osteoporosis prevention.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c5c47ab-28ee-11e1-bfc2-0800200c9a66",
      "source_locator": "Sections 1 and 2; application instructions",
      "checked": "2026-09-16",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "combipatch",
      "name": "CombiPatch",
      "ingredient": "estradiol + norethindrone acetate",
      "form": "Skin patch",
      "routine": "Follow the prescribed patch regimen",
      "indication": "Menopausal symptoms under the product label",
      "safety": "Contains estrogen and a progestin; not estrogen alone.",
      "source": "https://combipatch.com/pdfs/prescribing-information.pdf",
      "source_locator": "Description; indications; dosage",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "bijuva",
      "name": "Bijuva",
      "ingredient": "estradiol + progesterone",
      "form": "Oral capsule",
      "routine": "One capsule each evening with food",
      "indication": "Moderate-to-severe menopausal vasomotor symptoms in women with a uterus",
      "safety": "Contains estradiol and progesterone; contraindications require individual review.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc52489a-5149-411d-9665-2c75405ad15d",
      "source_locator": "Sections 1–5; February 2026 revision",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "duavee",
      "name": "Duavee",
      "ingredient": "conjugated estrogens + bazedoxifene",
      "form": "Oral tablet",
      "routine": "One tablet daily",
      "indication": "Vasomotor symptoms and osteoporosis prevention in women with a uterus",
      "safety": "Bazedoxifene is not progesterone; do not add estrogen or progestins without prescriber review.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb",
      "source_locator": "Sections 1, 2 and 5",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "prometrium",
      "name": "Prometrium",
      "ingredient": "micronized progesterone",
      "form": "Oral capsule",
      "routine": "Use the prescribed strength and cycle",
      "indication": "Endometrial hyperplasia prevention with estrogen in the labeled population",
      "safety": "Cited capsules contain peanut oil; allergy and exact formulation matter.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889",
      "source_locator": "Indications; ingredients; contraindications",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "progesterone",
      "name": "Generic progesterone",
      "ingredient": "micronized progesterone",
      "form": "Oral capsule",
      "routine": "Use the prescribed strength and cycle",
      "indication": "Endometrial hyperplasia prevention with estrogen under this label",
      "safety": "The cited generic also contains peanut oil; verify the actual dispensed supplier.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8925bba-f002-4455-a28f-eb6a888b4fe6",
      "source_locator": "Indications; ingredients; contraindications",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "vagifem",
      "name": "Vagifem",
      "ingredient": "estradiol",
      "form": "Vaginal insert",
      "routine": "Daily for 2 weeks, then twice weekly under the label",
      "indication": "Atrophic vaginitis due to menopause",
      "safety": "Initial and maintenance quantities differ; not a systemic hot-flash indication.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5ad3cf6-dd96-4e64-af21-c1eee38d0b88",
      "source_locator": "Sections 1 and 2",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "estring",
      "name": "Estring",
      "ingredient": "estradiol",
      "form": "Vaginal ring",
      "routine": "One ring for 90 days",
      "indication": "Moderate-to-severe menopausal vulvar and vaginal atrophy symptoms",
      "safety": "Local symptom therapy; not interchangeable with a systemic ring.",
      "source": "https://labeling.pfizer.com/ShowLabeling.aspx?id=19628",
      "source_locator": "Indications; dosage; patient information",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "femring",
      "name": "Femring",
      "ingredient": "estradiol acetate",
      "form": "Vaginal ring",
      "routine": "One ring for 3 months; prescribed release strength matters",
      "indication": "Menopausal vasomotor symptoms and vulvovaginal atrophy",
      "safety": "Systemic estrogen delivered vaginally; not local-only therapy.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaa97f9-a9d1-c815-e053-2991aa0afb9e",
      "source_locator": "Sections 1 and 2; pharmacokinetics",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "estradiol-cream",
      "name": "Estradiol vaginal cream",
      "ingredient": "estradiol",
      "form": "Vaginal cream",
      "routine": "Prescribed grams and frequency determine tube duration",
      "indication": "Vulvar and vaginal atrophy symptoms",
      "safety": "Cream amount and starting versus maintenance use affect the comparison.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb7b442d-b8c3-b7f0-e053-2a95a90a2c94",
      "source_locator": "Indications; dosage",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "osphena",
      "name": "Osphena",
      "ingredient": "ospemifene",
      "form": "Oral tablet",
      "routine": "Once daily",
      "indication": "Moderate-to-severe menopausal vaginal dryness and/or painful intercourse",
      "safety": "Estrogen receptor agonist/antagonist; endometrial and cardiovascular warnings.",
      "source": "https://osphena.com/",
      "source_locator": "Indication and important safety information",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    },
    {
      "id": "intrarosa",
      "name": "Intrarosa",
      "ingredient": "prasterone",
      "form": "Vaginal insert",
      "routine": "One 6.5 mg insert nightly",
      "indication": "Moderate-to-severe menopausal dyspareunia due to vulvovaginal atrophy",
      "safety": "Unexplained genital bleeding is a contraindication; review breast cancer history.",
      "source": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ada639d4-bac0-2ad0-e053-2a95a90afce7",
      "source_locator": "Sections 1–5; January 2026 revision",
      "checked": "2026-09-15",
      "scope": "Identity, indication and selected decision-relevant label facts only; not a complete label audit",
      "price": null,
      "stock": "not_verified",
      "clinical_review": "not_performed",
      "selected_identity_and_form_checked": "2026-09-17"
    }
  ],
  "last_reviewed": "2026-09-16",
  "catalog_updated": "2026-09-17"
}